sylated and non-mannosylated antigens were found in vesicles that contained markers typical for the MIIC and lysosomes. The mannose receptor itself, however, was never found in the MIIC, suggesting that it releases its ligand in an earlier endosomal structure and recycles back to the membrane. Moreover, we observed that mannosylation of peptide antigens led to an enhanced potency to stimulate HLA class I1 restricted, peptide-specific T-cells. Depending on the peptide used, 300-10000-fold less of a mannosylated peptide was required to stimulate these T-cells compared with a non-mannosylated peptide. These results indicate that the mannose receptor mediates internalization of ligand that is followed by transport to the MIIC, and that this leads to strongly enhanced antigen presentation by HLA class I1 molecules. These results may be of relevance for the design of improved vaccination strategies and the delivery of MHC-blocking peptides. They may also be useful to enhance antigen uptake by professional antigen-presenting cells, which could facilitate the identification of naturally processed, HLA-class-11-bound peptides derived from exogenous antigens.
Introduction
Studying autoimmune responses in man is not an easy task. Because there are few clues to how they are initiated, realistic animal models are rare. Furthermore, few of the target molecules are well characterized; in many of the best known cases they are sparse and can be produced in any quantity only by artificial manipulations in vim. A good example is the acetylcholine receptor (AChR) of muscle, which is attacked by the pathogenic autoantibodies in myasthenia gravis (MG). These heterogeneous high-affinity IgGs reduce AChR numbers partly by activating complement and also by accelerating receptor degradation [ 1, 2] . One important goal of research is to develop methods for selectively preventing or halting anti-AChR antibody production without global immunosuppression and its undesirable side-effects. In experimental models this response clearly depends on specific helper T-cells [3, 4] ; these seem promising targets for such immunotherapy because they may prove to be more restricted than the autoantibodies which might, in any case, block specific Abbreviations used: AChR, acetylcholine receptor; APC, antigen-presenting cells; MG, myasthenia gravis; Mabs, mouse monoclonal antibodies; TCR, T-cell receptor(s) .
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immunotherapeutic agents in the circulation. Hence one of the first critical issues is the heterogeneity of the pathogenic T-cells; this has been studied by a variety of approaches.
The AChR antigen, the antibodies and the myasthenic patients
Motor endplates cover a tiny fraction of the muscle surface but the AChRs are very concentrated there. They consist of four evolutionarily related subunits, u (represented twice), p, 6 and E , of 50-55 kDa. Each has about 210 amino acid residues in its highly folded extracellular domain, followed by four transmembrane segments; there is a cytoplasmic loop of roughly 100 residues between the last two [ S ] . Together they form an ion channel that opens in response to the binding of transmitter to external sites on the a/6 and a / & interfaces [6] . The u subunits are thought to be immunodominant in the T-cell response [7] , and the a67-76 sequence also makes a major contribution to the main immunogenic region that is recognized by many of the patients' autoantibodies [8] . However, these only bind minimally to unfolded subunits, even though the isolated cytoplasmic sequence in particular can readily evoke antibodies (in animals) that cross-react with whole AChR [9] . Thus the patients' specific B-cells must presumably also bind the AChR in its native conforma-tion before presenting fragments to the helper T-cells that activate them. However, these B-cells might represent the end stage of a process of determinant spreading [lo] . This could start with a low-affinity response to a cross-reacting unfolded fragment such as may be expressed in the thymic epithelial tumours found in about 10% of MG patients [4] . This could then elicit antibodies reacting weakly with the densely packed AChR at the endplate, and these in turn might help to immunize against its native conformation [ll] . In another subgroup of Caucasian patients, disease onset is between puberty and 40 years of age, and there is a 4:l female bias and a strong association with the MHC class I1 allele HLA-DR3, and especially with HLA-B8 in class I [1, 2] . These patients frequently show lymph node-like infiltrates in their thymic medulla, where rare muscle-like myoid cells express AChR [12] , and arguably may even initiate the response [13] . Furthermore their MG often ameliorates after thymectomy [14] .
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The T-cell response to AChR
The only rich source of native AChR is the electric organs of fish such as Torpedo and Electrophorus. Initially, therefore, Torpedo AChR was widely used for studies in vitro on MG patients and controls , in view of the strong sequence conservation; the a subunit is about 80% identical in man, although for the others the figure is 35-50% [5] . Thus the first supposedly autoimmune human T-cell lines were selected against purified Torpedo AChR [16] ; although they apparently cross-reacted with human receptor, subsequent T-cell lines selected with mammalian antigen [18] [19] [20] , and patients' serum antibodies [ 1, 2] , rarely recognize Torpedo AChR. Where T-cell epitopes have been defined [18] [19] [20] , there are often crucial TorpedoIhuman differences in anchor residues for class I1 or in contact residues for the T-cell receptor (TCR) [4, 18, 20] . That might reflect a preference for the more variable extracellular sequence rather than the highly conserved transmembrane segments.
The recombinant approach
More recently, because the human AChR subunit genes have all been cloned and sequenced [5] , we and others have expressed them in Escherichia coli and purified polypeptides by solubilizing inclusion body preparations with detergent (0.5% N-lauroyl sarcosine) [21] . Especially by using the T 7 bacteriophage promoter in the PET expression system [22] , we have been able to produce a range of polypeptides covering different regions of the human a subunit, which have helped greatly in mapping T-cell epitopes [18] [19] [20] 231 . When expressed at very high levels, some of them also react significantly with mouse monoclonal antibodies (Mabs) to the human AChR, even though these largely require its native conformation. These products may thus have refolded, at least partially, and sometimes bind weakly to patients' serum antibodies. They have also proved invaluable for studying specific T-cells that recognize unfolded peptide fragments.
Using nearly full-length a-subunit polypeptides, we have selected five T-cell lines/ clones that we have characterized in detail, identifylng their exact peptide -and MHC class I1 -specificities (Table 1 ). So far, the epitopes have all mapped to the extracellular domain, three being very near to the main immunogenic region (a67-76). Intriguingly, the other two recognize exactly the same a149-156 sequence, which is very close to the only N-glycosylation site (at AS^'^') and to an intra-chain disulphide bond (Cy~'~-Cys'~*); perhaps these enhance its processing. Although common in the donor panel, HLA-DR3 and the linked DQw2 have not yet proved to be dominant restricting elements. Instead these include 'minority' DR52a, DR53, DQ and DP molecules that are supposedly expressed at low levels on peripheral APC [24] . In addition, one line from a healthy control behaved similarly, although studied in less detail [ 19, 201 , and recognized an apparently recurring DR53-restricted a45-63 epitope [20, 23] . Above all, these T-cells all proved to be remarkably sensitive, not only to a range of (po1y)peptides spanning their 'core', but also to minute concentrations of AChR purified from human muscle [18] [19] [20] 251 . Such defined specificity for epitopes naturally processed from the whole receptor has not been rigorously documented for other supposedly AChR-responsive T-cells.
This approach nevertheless has serious limitations, as described below.
1. The approach's success rate is low, and it is very laborious. Because of their great sensitivity, T-cells specific for a variety of contaminating E. coli proteins are selected all too easily, however pure the antigen preparations seem to be [20] . Much effort is inevitably wasted because 2. Because, even in high-titre MG sera, the anti-AChR antibodies only represent around 1 in lo4 IgG molecules, one might expect the precursor frequency of specific T-cells to be similarly low, and that must surely limit the success rate in their isolation. Furthermore they appear not to congregate in muscle [28] , so that the target organ is not a rich source for cloning, as it is, for example, in thyroid autoimmunity [29] . Indeed, the production of anti-AChR antibodies seems to be widespread, for instance in lymph nodes and bone marrow as well as in the thymus, where their specific activity seems to be highest 3. If the responder B-cells recognize AChR only in its native form, the use of unfolded polypeptides that they cannot bind efficiently might bypass this most relevant of processing mechanisms, which might also be employed by other antigen-presenting cells (APC) that bind antigen-antibody complexes or use cytophilic antibodies. The responses that we do see might be a result of the partial refolding mentioned above; if this could be improved, or if native AChR could be purified in quantity, the success rate might be further enhanced. The sensitivity of our clones to whole AChR clearly shows that responsive T-cells do exist in the patients.
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Because the autoimmune response might well begin months or years before the onset of symptoms, many pathogenic T-cells could well be quiescing or even anergic by the time of diagnosis. Alternatively, their key role in pathogenesis might be to produce cytokines and activate a B-cell response without themselves proliferating greatly, either in the donor patient or when we attempt to stimulate in vitm [30] . In theory, also, some T-cells could be specific for unusuallcryptic antigen products, resulting, for example, from translation beyond a normal stop codon or into an intron [31] . The recognition by one of our clones of the recently identified P3A insert [32] is a sign of alternative splicing rather than eccentric translation.
The synthetic approach
Because of these difficulties, several groups have used individual or pooled synthetic peptides synthesized from the sequences of AChR subunits to study the responses of fresh T-cells [33, 34] Because of the contrasts with our previous results, we decided to study a similar series of T-cell lines selected with our most potent synthetic peptides, either pooled or individually [20, 23] . We too found it easy to raise such lines from healthy controls as well as patients, and we noted a similar heterogeneity. However, using these peptides, we twice failed to recall responses from the same patients to the epitopes recognized by their previous clones [23] . As in other studies, we observed recurring responses to a few regions, especially a62-115, a138-167 and a309-344. Although this appeared to reflect a clustering of binding motifs for different class I1 alleles in these sequences [39] , recurring recognition of these epitopes was not obvious in the different studies (discussed in [23] ), although it might have been expected if there were a limited range of dominant natural epitopes. We also noted that some of these T-cells required high concentrations of peptides, especially when these were used to pre-pulse the APC [23] , apparently reflecting a preference for more weakly class 11-binding epitopes [39] .
Most strikingly, even after systematic checking at different phases of the evolution of these lines, we never found any significant responses to whole AChR or even to any of our recombinant polypeptides [23] . Among the 20 sublines tested, the only partial exception was one line specific for a310-327; it could respond to recombinant (r)265-366, but only after it had been artificially degraded by treatment with trypsin or freezethawing. Four of the others were clearly specific for contaminants in the original peptide sequences and failed to respond to resynthesized versions of them. Even one of the most sensitive sublines, which recognized multiple peptides overlapping its 149-156 core, has subsequently proved to depend on some synthetic error, perhaps a persisting protecting group, a mini-deletion or a racemic residue. Such contaminants in synthetic peptides are evidently a more widespread problem than we originally suspected, and one that is insufficiently emphasized in the literature.
Thus our overwhelming conclusions are that, although this synthetic approach might help to locate potential class 11-binding sequences, it rarely selects T-cells that can recognize naturally processed epitopes from AChR at physiological concentrations, and therefore gives a greatly exaggerated impression of heterogeneity. The truly pathogenic T-cells might yet prove to be much more restricted, and the prospects for selective immunotherapy remain bright.
Towards specific immunotherapy
In animal models of multiple sclerosis, several approaches have given promising results [40, 41] . Some of them rely on immunizing a subset of inhibitory T-cells that can home to the brain; there they dampen the response, regardless of its precise specificity, as long as they can recognize some tissue-specific antigen(s) [41] . In contrast, in MG, the responding cells are not confined to muscle; reagents are therefore needed that can circulate and enter the tissues freely. An important general strategy is to engage the T-cell receptor (TCR) without optimal co-stimulation, to induce a state of specific and long-lasting unresponsiveness [42] . In principle, that can be done with Mabs against the TCR; alternatively one can use peptide plus MHC alone -either on cells with inactivated accessory molecules (e.g. after fixation) or in free solution -an approach pioneered by Sharma et al. [43] . Because human T-cell clones themselves strongly express class I1 without optimal accessory molecules, merely incubating them with excess free peptide achieves the first of these aims.
We have compared the effects of prior exposure of our T-cell clone PM-A1 to these reagents in the absence of APC (Table 2) . Whereas an anti-Vg5.1 Mab causes a rapid blockade of the TCR (within minutes), soluble peptide-DR4 complexes or free peptide take several hours to inhibit responses to a subsequent challenge with antigen plus APC [44] . These effects are highly specific for the peptide and the class I1 allele (Figure 1 ) [44] . When both are correct, we observe apoptosis in many more of the T-cells after exposure to the complex than to the Mab (Table 2) . Moreover, the surviving cells remain unresponsive for many days [44] , whereas after Mab treatment they begin to recover within 24 h. With free peptide the effects are intermediate; as with the soluble complex, however, it can be converted into a stronger stimulus by addition even of mismatched bystander APC [44] , i.e. by providing co-stimulation while the TCR is engaged.
Before application in patients, many crucial issues remain to be resolved: the importance of monomeric compared with aggregated complexes; how to enhance apoptosis; the differences in TCR signals evoked by complexes and Mabs; which subsets of T-cells are the most pathogenic, and whether some are protective; which of
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The Molecular Biology of Autoantigens Table 2 Unresponsiveness induced in PM-A T-cells by soluble DR4-peptide complexes, free peptide or anti-TCR Mab IC50 is the concentration required to inhibit 509b of the response to an optimal challenge with APC and recombinant antigen. these are more susceptible to this therapy, especially in their natural state in vivo; which epitopes and class I1 restrictions recur most frequently in different patients. There will inevitably be difficulties along the way, e.g. with preparing sufficient quantities of complex, with its persistence and pervasiveness in vivo, and with avoidance of bystander co-stimulation. However, there should be rich rewards if these can be circumvented, because the complexes have major advantages over other strategies, especially their selectivity for the least diverse facet of the response and their ability to induce apoptosis.
